Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Economic information and modeling report

Modeling overview

6 evidence topics · 7 sources

Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found, and no price for it has been published. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then”, and its presentation describes first-line recurrent or metastatic HPV-negative HNSCC as “a global commercial opportunity of ~$5B+ annually by 2030”. Three published U.S. payer models address first-line comparators. Borse et al. (2022) used a three-state partitioned-survival model over 20 years with 3% annual discounting: pembrolizumab monotherapy was dominant versus the EXTREME regimen in the CPS ≥1 population, and pembrolizumab combination therapy was cost-effective versus EXTREME at $1769/QALY in the overall population. In the Markov model of She et al. (2022), pembrolizumab plus chemotherapy versus cetuximab plus chemotherapy yielded ICERs of $147876.14, $134237.84, and $153660.78 per QALY in the total, CPS ≥1, and CPS ≥20 populations. Ye et al. (2024), using a 15-year three-state partitioned survival model, found the EXTREME regimen cost-effective compared with nivolumab plus ipilimumab at a willingness-to-pay threshold of $150,000/QALY. None of these models includes ficerafusp alfa.

Budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa

No evidence found.